

1 **Plasma multi-omics outlines association of urobilinogen with corticosteroid**
2 **non-response, inflammation and leaky gut in Sever Alcoholic Hepatitis**

3 Manisha Yadav^{1#}, Babu Mathew¹, Sadam H Bhat¹, Neha Sharma¹, Jitender Kumar¹, Pushpa
4 Yadav¹, Gaurav Tripathi¹, Vasundhra Bindal¹, Nupur Sharma¹, Sushmita Pandey¹, Ravinder
5 Singh¹, Ashima Bhaskar², Ved Prakash Dwivedi², Nirupama Trehanpati¹, Shvetank Sharma¹,
6 Shiv Kumar Sarin^{3*} and Jaswinder Singh Maras^{1#*}

7 ¹ Department of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences, New
8 Delhi.

9 ² International Centre for Genetic Engineering and Biotechnology, New Delhi.

10 ³ Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi.

11

12 # Equal contribution.

13 *Correspondence:*

14 *Dr. Jaswinder Singh Maras*

15 *Assistant Professor*

16 *Department of Molecular and Cellular Medicine,*

17 *Institute of Liver and Biliary Sciences, New Delhi-110070, India*

18 jassilparam@gmail.com

19 *Tel: 011 46300000 ext-14115*

20

21 *Correspondence:*

22 *Dr. Shiv Kumar Sarin*

23 *Senior Professor*

24 *Department of Hepatology,*

25 *Institute of Liver and Biliary Sciences, New Delhi-110070, India*

26 *Tel: 011-46300000, Fax 011-26123504*

27

28 *Disclosure:* All authors have declared no conflict of interest.

29 *Financial Support:* The work was supported from project DST (DST-SERB)
30 (EMR/1016/004819)

1 *Authors' contribution:* JSM, SKS conceptualized the work. JSM, MY and BM were responsible
2 for sample processing and experimental work and were helped by NS, SHB, JK, PY, GT, VB,
3 NS, SP, RS and MI. Data analysis was performed by MY under the guidance of JSM. The
4 manuscript was drafted by MY, JSM and SKS. This manuscript has been seen approved by all
5 authors.

6 **Key Words:** plasma metabolome, metaproteome, urobilinogen, inflammation, severe alcoholic
7 hepatitis, responders, non-responders, and corticosteroid therapy.

8 Short Title: **Bacteria derived urobilinogen induces inflammation, intestinal permeability**
9 **and predicts outcome in Severe Alcoholic Hepatitis.**

10 Abbreviations:

11	SAH	Severe Alcoholic Hepatitis
12	R	Responders
13	NR	Non-responders
14	DF	Discriminant Factor
15	DEMs	Differentially Expressed Metabolites
16	GR	Glucocorticoid Receptor
17	H2DCFDA	1',7'-dichlorodihydrofluorescein diacetate
18	MFI	Mean fluorescence intensity
19	ML	Machine Learning
20	MS	Mass Spectrometry
21	PLS-DA	Partial Least Square Discriminant Analysis
22	PHN	Primary Human Neutrophils
23	PME	Primary Mice Enterocytes
24	Pred	Prednisolone
25	U	Urobilinogen
26	WMCNA	Weighted Metabolome Correlation Network Analysis

27

28

29

1 **ABSTRACT**

2 **Background and Aims:** Severe alcoholic hepatitis (SAH) has a high mortality and
3 corticosteroid therapy is effective in 60% patients. Reliable indicators of response to therapy and
4 mortality in SAH are needed. A total of 223 SAH patients, 70 in derivation [50 responders (R)
5 and 20 non-responders (NR)] and 153 in validation cohort [136R, 17NR] were subjected to
6 plasma metabolic/meta-proteomic analysis using UHPLC-HRMS and validated using Machine-
7 Learning (ML). Temporal metabolic changes were assessed using Weighted Metabolome
8 Correlation Network Analysis (WMCNA). Functionality (inflammatory-nature, effect on
9 membrane integrity and glucocorticoid receptor) of non-response indicator was assessed *in-vitro*
10 on primary healthy neutrophils or mice enterocytes. Baseline plasma metabolomics and meta-
11 proteomics clearly discriminated NR and showed significant increase in urobilinogen (3.6-fold),
12 cholesterol sulfate (6.9-fold), Adenosine monophosphate (4.7-fold) and others ($p<0.05$, $FC>1.5$,
13 $FDR<0.01$). Increase in alpha/beta diversity, biosynthesis of secondary metabolites was a
14 characteristic feature of NR ($p<0.05$). NR were metabolically inactive however R showed
15 temporal change in the metabolite expression post-corticosteroid therapy ($p<0.05$). Plasma
16 urobilinogen predicted non-response [AUC=0.94] with a hazard-ratio of 1.5(1.2-1.6) and cut-off
17 $>0.07\text{mg/ml}$ segregated non-survivors ($p<0.01$) and showed $>98\%$ accuracy using ML. Plasma
18 urobilinogen directly correlated with circulating bacterial peptides linked to bilirubin to
19 urobilinogen metabolising bacteria ($r^2>0.7$; $p<0.05$). Urobilinogen induced **neutrophil**
20 **activation**, **oxidative-stress** and **pro-inflammatory cytokines** (CXCR1, NGAL, NOXO1,
21 NOX4, IL15, TNF α and others, $p<0.05$), promoted **corticosteroid resistance** by increasing the
22 expression of GR-Beta and trans-repression genes under GR-alpha (inflammatory-NF κ B,
23 MAPK-MAP) and reducing GR-alpha, and transactivation (anti-inflammatory) gene levels.
24 Urobilinogen also promoted leaky gut by deregulating intestinal membrane junction proteins.
25 **Conclusion:** Plasma metabolome/meta-proteome can stratify pre-therapy steroid response.
26 Increase in plasma Urobilinogen pedals a vicious cycle of bacterial translocation and increase in
27 inflammation and corticosteroid non-response in SAH patients.

28

1 **Introduction:**

2 Severe Alcoholic Hepatitis (SAH) is often associated with systemic inflammatory response
3 syndrome, organ failure and high short-term mortality (1). Model for End-Stage Liver Disease
4 (MELD) score ≥ 20 and a Maddrey's Discriminant Function (mDF) score ≥ 31 are used as cut-offs
5 to deduce the severity in SAH (3, 4). For decades, liver transplant has been the only effective
6 treatment. Corticosteroid therapy used as a standard medical care (5) improves short-term
7 survival and is effective only in 60% of SAH patients (6). Over-exposure of corticosteroids
8 increases predisposition to secondary bacterial infections, sepsis and early mortality in SAH (7,
9 8). Therefore, reliable indicators capable of segregating NR and R and can help us in
10 determining the efficacies of corticosteroids in SAH are needed.

11 Further, untargeted plasma metabolomics is now actively promulgated to evaluate
12 mechanisms underlying various pathologies (10, 11). Recently, Moreau et al. documented the
13 utility of plasma metabolomics in showcasing that inflammation-associated mitochondrial
14 dysfunction is a potential mechanism underlying ACLF patients (11). Javier Michelena et al. also
15 worked on serum samples and showed the utility of metabolomic markers in accurate, non-
16 invasive diagnosis and prognosis of alcoholic hepatitis (13). For SAH patients particularly on
17 corticosteroid therapy such plasma based indicators which could predict response are of urgent
18 need.

19 Dysbiosis is an unfavourable pathological event seen in SAH patients and presence of
20 circulating microbial products can result in persistent stimulation of immune system (14) (15).
21 Further prolong exposure of corticosteroids increases the risk of bacterial infection, sepsis and
22 other complications (16). Recently, an increase in alcohol consumption has been proposed as the
23 primary driver in changing circulating microbiomes (17). Therefore, robust analysis of the
24 circulating bacterial peptide, microbial products and associated functions in corticosteroid
25 responders and non-responders is warranted.

26 Increase in the circulatory bilirubin and urobilinoids are associated with high severity in
27 SAH patients (18). Intestinal flora converts bilirubin to urobilinogen, 82% of which is
28 transported to the kidney and excreted out through urine or converted to stercobilin or urobilin
29 and then excreted out via feces (19). Recently, pro-inflammatory nature of stercobilin has been
30 documented (10) but urobilinogen being the major urobilinoid has not been studied so far. Since
31 bilirubin metabolism is bacterial driven and dysbiosis is often seen in the pathogenesis of SAH, it

1 becomes necessary to gain insight into the overall metabolic state and the host-microbiome
2 interactions in the plasma of SAH.

3 In the current study, the overall metabolic status and circulating microbiome of SAH
4 patients was studied using plasma metabolomics and meta-proteomics respectively. Baseline
5 plasma metabolic indicator which could segregate responders from non-responders correlates
6 with disease severity and mortality at baseline was identified. Temporal changes in the metabolic
7 phenotype post corticosteroid therapy in R and NR were also studied. Baseline meta-proteome
8 (microbiome) was correlated with the baseline metabolome to understand the host-microbiome
9 interactions. Results found an increase in bacteria associated with Urobilinogen (metabolic
10 indicator of NR and outcome) in NR-SAH. Finally, functional properties (inflammatory nature,
11 effect on membrane integrity, glucocorticoid receptor and downstream signalling) of identified
12 marker were assessed in-vitro on primary healthy neutrophils (PHN) and its role in modulating
13 intestinal permeability was studied on primary mice enterocytes (PME).

14

1 **Patients and Methods**

2 SAH patients seen at Department of Hepatology, Institute of Liver and Biliary Science, New
3 Delhi, India (2017-2020), and confirmed to have mDF >31, recent onset of jaundice, chronic
4 alcohol abuse, and liver biochemistry and histologic features of SAH (n= 250) were screened for
5 corticosteroid therapy (6). 27 patients were excluded due to presence of hepatitis B and C virus,
6 hepatocellular carcinoma, portal vein thrombosis, or recent variceal bleed. Written informed
7 consent was obtained from all the patients and the study was approved by the Institutional Ethics
8 Committee.

9 Baseline demographic profile and clinical characteristics of all SAH patients were
10 recorded. Plasma samples were collected at baseline and after day-3 and day-7 of prednisolone
11 therapy (given as standard of care in SAH patients) (40mg/day) initiation. Patients were
12 characterized as R and NR based on day-7 Lille's score (6). SAH patients were randomly
13 distributed into the derivative and validation cohort, where both the clinical and the laboratory
14 personals were kept blind for grouping. In brief, of the 223 patients, 70 patients (30%) were
15 grouped in derivative cohort, and the remaining 153 patients (70%) were grouped in validation
16 cohort. Leads from the metabolomic studies in the derivative cohort were validated using high
17 resolution MS and ML in the validation cohort.

18 **Untargeted Metabolomics and Meta-proteomics analysis using UHPLC High Resolution-** 19 **MS:**

20 Untargeted metabolomic and meta-proteomic analyses of plasma samples were performed as
21 detailed in **supplementary methods**.

22 **Construction of Weighted Metabolome Co-Expression Network (WMCNA):** Method
23 involved in the construction of WMCNA and Module Trait Relationship is detailed in
24 **supplementary methods**.

25 **Neutrophil Activation and oxidative Assay:** PHN (>98% pure) were treated with urobilinogen
26 (5 to 120 μ M), LPS-10ng/ml and PMA-10ng/ml. CD66b+PE and CD11b+PECy7 (neutrophil
27 markers) neutrophil populations were assessed for activation and inflammation markers using
28 anti-CXCR1-BV510, and anti-TNF α -PerCPCy5.5 respectively. Intracellular ROS was measured
29 by using 1 μ M 1',7'-dichlorodihydrofluorescein diacetate (H2DCFDA). Mean fluorescence

1 intensity (MFI) for CD66b+, CD11b+, CXCR1+, TNFa+, and (H2DCFDA) ROS was measured
2 using Flow Cytometry.

3 **Semi-quantitative RT-PCR Analysis:**

4 Neutrophil activation and inflammation status was studied using a panel of 17 genes associated
5 with activation (NGAL), intracellular antioxidants (CCS, GSR, SOD1, SOD1, and SOD3), ROS
6 production (NOXO1, NOXA1, NOX4, and NOX1) and inflammatory cytokines (IL15, IL7, IL4,
7 TNFa, IL8, IL6, and IL11) (11).

8 **Proteomic analysis of activated neutrophil and primary mice enterocytes:**

9 PHN and PME were isolated as detailed in supplementary methods. Neutrophils treated with
10 urobilinogen (effective dose: 60uM), PMA, LPS, U+Pred, PMA+Pred, LPS+Pred, PMA+U,
11 PMA+U+Pred, LPS+U and LPS+U+Pred were subjected to proteomic analysis as detailed in the
12 **supplementary method**. PME were treated with urobilinogen (effective dose: 60uM) alone,
13 LPS (30ng/ml) and Alcohol (5%) in presence and absence of U for 90 min and were subjected to
14 proteomic analysis as detailed in the **supplementary method**.

15 **Statistical Analysis**

16 Results are shown as mean and SD unless indicated otherwise. Statistical analysis was performed
17 using Graph Pad Prism-version 6.0, and SPSS-version 10; and p-values <0.05 using Benjamini-
18 Hochberg correction were considered significant. Unpaired (two-tailed) Student t-test and the
19 Mann-Whitney U-test were performed for comparison of two groups. For temporal analysis a
20 paired t-test was performed. For comparison among more than two groups, ANOVA and the
21 Kruskal-Wallis tests were performed. All correlations were performed using Spearman
22 correlation analysis, and $R^1 > 0.5$ and $p < 0.05$ were considered statistically significant. Potential
23 metabolic candidates with highest AUC, FC, and significant p-value were identified at baseline
24 to predict non-responsiveness. Comparative AUROC analysis was performed for top identified
25 metabolite and other clinical variables such as DF, CTP, and MELD score in order to compute
26 sensitivity and specificity and to obtain cut-offs for each variable. Based on the AUROC
27 diagnostic cut-off, prediction of mortality was performed using Kaplan–Meier method and
28 compared between the two groups (log-rank test, hazard ratio, and 95% confidence limit
29 estimated using Cox regression Model). The metabolic indicator identified in the derivative
30 cohort was then validated using MS and ML.

1 **Machine Learning Validation:**

2 Five different ML algorithms: LDA (Linear Discriminant Analysis), KNN (K-Nearest
3 Neighbor), CART (Classification and Regression Tree), SVM (Support Vector Machine), and
4 RF (Random Forest) were used to validate and compare the sensitivity and specificity of
5 candidate indicators with clinical variables such as MELD, CTP and mDF as detailed in
6 **supplementary methods.**

7

8

1 **RESULTS:**

2 **Patient Characterization:**

3 Baseline demographic profile of NR and R in both the derivative and validation cohorts was
4 similar except for platelet count, leukocyte count and 90 day mortality, which were significantly
5 higher in NR (Supplementary table-1).

6 **Characterization of Baseline Plasma Metabolome and Meta-Proteome:**

7 Plasma metabolomics (discovery cohort) led to the identification of 10164 and 13084 features in
8 negative and positive electrospray ionization mode. Of them, 711 features were annotated based
9 on m/z matching structure (spectral database), retention time and/or mass. Functionally these
10 metabolites showed enrichment of amino acids, fatty acids, mono-saccharides, purines,
11 pyrimidine, indoles, steroids, TCA, quinone, bilirubin, bile acids, and others super-classes
12 ($p < 0.05$) (Supplementary figure-1, Supplementary table-2). Plasma Meta-proteome analysis
13 identified 349 unique peptide sequences belonging to different class of bacteria (Supplementary
14 figure-2, supplementary table-3).

15 **Baseline Plasma Metabolome Robustly Distinguishes Non Responders:**

16 The flow chart in Figure 1A explains the study design. Untargeted metabolomics was performed
17 in plasma samples of 223 SAH patients at baseline, day3, and day7, and temporal changes in the
18 metabolic profile were studied at baseline, day3, and day7. Meta-proteome profile was studied at
19 baseline and correlated with metabolome profile to identify metabolite-microbiome interactions
20 in SAH. Metabolite indicator of non-response and early mortality was identified and validated
21 using MS and ML (Figure 1A).

22 A total of 193 (149 up-, 44 down-regulated) DEMs were identified at baseline in NR
23 compared to R ($p < 0.05$; Figure 1B, Supplementary table-4). PLS-DA analysis significantly
24 segregated NR from R (Figure 1C, loading plot: Supplementary figure-3). NR showed a
25 significant increase in metabolites associated with taurine/hypo-aurine metabolism, alanine,
26 aspartate, and glutamate metabolism, linoleic acid metabolism, and others ($p < 0.05$; Figure 1D)
27 whereas metabolites linked to pyrimidine metabolism, histidine metabolism, and others, were
28 decreased in NR ($p < 0.05$; Figure 1E). Together these results suggest that the metabolic profile of
29 NR is distinct from R and shows increased catabolism of amino acid, fatty acid, and others which

1 functions as the fuel for the activation of immune cells. These differences could be exploited for
2 the stratification of NR from R.

3 **WMCNA highlights Corticosteroid mediated changes in the metabolic profile are more**
4 **pronounced in responders:**

5 To gain insights into the temporal changes that occurred upon corticosteroid administration in
6 NR and R, plasma metabolome of baseline, day3 and day7 were compared. The expression of a
7 plethora of metabolites got significantly downregulated in NR by day3 and day7 post steroid
8 administration (Figure 2A, Supplement table-5). PLS-DA analysis showed a time-wise
9 segregation of R from NR, suggesting metabolic variability in these patients (Figure 2B).
10 Clustering analysis showed the inactive metabolic status of NR post-corticosteroid
11 administration as the expression of metabolites barely changed over time whereas, in R, the
12 metabolic profile changed in a temporal manner (Figure 2B).

13 Metabolic profiles of NR and R on day0, day3, and day7 were subjected to WMCNA to identify
14 metabolic modules (metabolite clusters showing a similar trend in their expression over time)
15 specific to R, NR, and severity indices. WMCNA clustered 711 metabolites into 9 modules
16 (Figure 2C). The heatmap clearly shows activation and inhibition of a myriad of metabolites in R
17 upon corticosteroid exposure and almost no effect of corticosteroid therapy in NR (Figure 2C).
18 Module trait relationship (phenotype of R and NR at baseline, day3, and day7 are referred to as a
19 trait) clustering analysis (Figure 2D) identified the 'Pink' module specific to R (up-regulated at
20 baseline) which was linked to histidine and seleno-compound metabolism, whereas 'Red' module
21 specific to NR (up-regulated at baseline) linked to steroid hormone biosynthesis and vitamin B6
22 metabolism (Figure 2D, and 2E). Metabolites in the 'Blue' and 'Turquoise' modules temporally
23 increased in R (Figure 2D) and were associated with pathways linked to Citrate cycle (TCA
24 cycle), Arginine biosynthesis, Glutathione metabolism, Tyrosine metabolism,
25 Glycolysis/Gluconeogenesis, and others (Figure 2E). The statistical composition of each
26 metabolite module is shown in Supplementary figure 7. At baseline NR specific 'Red' module
27 correlated directly with the severity indices (MELD, CTP, DF, and others) whereas response-
28 specific modules such as 'Pink', 'Blue', and 'Turquoise' correlated inversely with the severity
29 indices from baseline to day 7 (Figure 2F). Hence WMCNA confirmed the notion that
30 Corticosteroid therapy changes the metabolic profile only in R. The metabolic profile of NR

1 remained almost unchanged upon corticosteroid administration with a predominant increase in
2 steroid hormone biosynthesis. Further, up-regulation of the 'Blue' and 'Turquoise' modules
3 reflects responsiveness to corticosteroid therapy in R.

4 **MS analysis and Machine learning validates that baseline plasma Level of Urobilinogen**
5 **indicates non-response and correlates with Outcome in SAH Patients:**

6 The flow chart in Figure 3A explains the approach adopted to identify the metabolic indicator
7 capable of segregating NR at baseline. In the derivative cohort, a panel of 8 metabolites
8 (C05791-urobilinogen, C18043-cholesterol sulphate, C00020-AMP, C00439- formimidoyl-L-
9 glutamate, C00078-tryptophan, C01835-maltotriose, C00785-urocanic acid, and C00178-
10 thymine) based on significant p-value, high AUC and FC ± 1.5 folds (Figure 3B) were selected
11 which could segregate NR from R at baseline and were validated in a separate cohort of SAH
12 patients (NR=17, R=136) (Figure 4B). C05791; Urobilinogen was selected as a metabolic
13 indicator of non-response at baseline as it showed the highest AUROC value of 0.947 among all
14 other selected metabolites (Figure 3C, Supplementary figure-8). COX multivariate analysis also
15 identified urobilinogen as an independent predictor of mortality with a maximum Hazard Ratio
16 (HR-1.469) (Figure 3C). Further, based on the AUROC of urobilinogen of 0.947 and the
17 likelihood ratio of 3.1, a cut-off of 0.07 mg/ml was determined to assess the survival in SAH
18 patients. Patients with urobilinogen levels higher than 0.07mg/ml showed higher mortality (log-
19 rank <0.01 , Figure 3D, Supplementary figure 9, and 10). When compared to other clinical factors
20 (MELD, DF, and CTP), urobilinogen attained the highest AUROC of 0.83 (0.76-0.90) for the
21 prediction of poor outcomes in SAH (Figure 3E). Together these results suggest urobilinogen as
22 an independent predictor of corticosteroid response and short-term mortality in SAH patients.

23 ***Machine Learning-based validation of urobilinogen as independent predictor of mortality in***
24 ***SAH:*** 223 SAH patients were randomly divided into the training cohort (70% sample strength)
25 and the test cohort (30% sample strength). A total of 5 ML algorithms LDA, KNN, RF, SVM,
26 and CART were used (supplementary method). Four parameters - Accuracy, sensitivity,
27 specificity, and p-value - were calculated for baseline Urobilinogen (C05791), baseline MELD,
28 mDF, and CTP scores for mortality prediction in our study cohort. Twenty ML models were
29 generated across the 4 parameters. Fourfold (outer) nested repeated (five times) tenfold (inner)
30 cross-validation was used to train and test ML models, and the hyper-parameters of each

1 algorithm were optimized. Accuracy and kappa of model development (training cohort) were
2 significant for all the parameters (Supplementary figure-11). The prediction capability of
3 Urobilinogen was found to be highest with accuracy (98%), sensitivity (99%), specificity
4 (98.3%), and $p < 0.00001$ as compared to MELD, mDF, and CTP scores (Figure 3F) validating
5 the utility of urobilinogen as a candidate indicator and Random forest (RF) model as the model
6 of choice for machine learning in SAH patients.

7 **Baseline plasma meta-proteomics (microbiome) of Non-Responders reflects increase in** 8 **production of secondary metabolites:**

9 Certain intestinal bacteria belonging to *Clostridiales* are known to convert bilirubin to
10 urobilinogen (10). Our data showed a significant increase in bilirubin metabolic by-products in
11 the plasma of NR ($p < 0.05$, Figure 4A). Thus circulating microbiome (metaproteomic) profile of
12 NR was compared to R. The alpha, beta diversity (Shannon, Spimson index; PCoA) and relative
13 abundance of bacteria in plasma of NR were significantly higher and distinct as compared to R
14 (Figure 4B, 4C, and 4D respectively). Particularly, NR showed a significant increase in bacterial
15 peptides associated with *Bacillus*, *Mycobacterium*, *Neisseria*, *Mycoplasma*, *Streptococcus*,
16 *Salmonella*, *Chlamydia*, *Bifidobacterium*, and many others (Figure 4E) known to be associated
17 with an increase in inflammation, infection, and severity. Functional enrichment of
18 metaproteome showed a predominant increase in biosynthesis of secondary metabolites, energy,
19 glycan, cofactors, and vitamin metabolism ($p < 0.05$, Figure 4F). Together, these results show that
20 the plasma of NR has higher bacterial diversity corresponding to an increase in bacterial peptides
21 and functions (particularly an increase in secondary metabolite biosynthesis).

22 **Correlation of plasma metabolome and meta-proteome identifies meta-proteome associated** 23 **with bacterial derived urobilinogen.**

24 As bacteria convert bilirubin to urobilinogen and in order to integrate the metabolome with meta-
25 proteome, baseline differentially expressed metabolome (DEM) was correlated to differentially
26 expressed meta-proteome (DEMp, Figure 5A). Correlation clustering identified 4 clusters
27 showing a strong positive correlation between metabolites and meta-proteomes (Figure 5B;
28 $R^1 > 0.5$, $p < 0.05$). Among these, Cluster 2 was the biggest cluster in which our candidate indicator
29 of NR and mortality (urobilinogen) showed a strong positive correlation ($R^1 > 0.5$) with meta-
30 proteins associated with bacteria; *Firmicutes* (*Clostridiales* and, *Streptococcus pneumonia* and

1 Hungatei clostridium), and *Proteobacteria* (Neisseriaceae) (Figure 5C). Expression of these
2 bacterial families and urobilinogen was significantly high in the plasma of NR as compared to R
3 ($p < 0.05$) (Figure 5D). These results clearly suggest that an increase in the plasma urobilinogen in
4 NR could be due to an increase in the level of bilirubin metabolizing bacteria particularly
5 belonging to *Clostridiales*.

6 **Urobilinogen activates neutrophils, induces respiratory burst and increases cellular** 7 **permeability:**

8 Data until now clearly showed that plasma level of urobilinogen significantly increased in NR
9 and is an independent predictor of poor outcomes in SAH. Our results also outlined that
10 increased urobilinogen levels correlated directly with bilirubin metabolizing bacteria. We,
11 therefore, speculated that this increase in circulatory urobilinogen may have immune-modulatory
12 properties.

13 *Urobilinogen activates neutrophils and induces respiratory burst:* To ascertain the immune-
14 modulatory properties of urobilinogen, primary healthy neutrophils (PHN) were exposed to
15 different concentrations (5uM to 120uM) of pure urobilinogen (CAS No. 14684-37-8,
16 MyBioSource) and mitogens like LPS (10ng/ml), PMA (10ng/ml) and H₂O₂ (0.001%) as
17 control. CD66b⁺/CD11b⁺ dual positive neutrophils showed a significant increase in activation,
18 pro-inflammatory and respiratory burst markers such as CXCR1, TNF α , and H₂DCFDA
19 expression (MFI) respectively at 60uM and 120uM doses of urobilinogen as seen in LPS, PMA
20 and H₂O₂ (Figure 6A). 60uM urobilinogen was considered for further experimentation as cell
21 death was observed at 120uM (Figure 6A).

22 Next, PHN treated with 60uM urobilinogen, PMA/LPS (positive controls), and in
23 combination (PMA/LPS + 60uM-urobilinogen) were challenged with 10uM Prednisolone.
24 PMA/LPS activated neutrophils (CD66b⁺/CD11b⁺/CXCR1⁺) showed a significant reduction in
25 oxidative stress and inflammatory cytokine production post prednisolone treatment but in
26 presence of urobilinogen (60uM) prednisolone couldn't effectively reduce the inflammation
27 suggesting that urobilinogen interferes with the activity of prednisolone (Figure 6A lower
28 panels).

29 This observation was further validated using qRT-PCR. The expression of genes linked
30 to neutrophil activation, oxidative stress, antioxidant response, and pro-inflammatory cytokines

1 was overlooked in PHN treated with PMA/LPS and PMA/LPS+60uM-
2 urobilinogen+prednisolone. On comparing PMA/LPS with PMA/LPS+60uM urobilinogen, we
3 observed a significant increase in expression of neutrophil activation (NGAL), oxidative stress
4 (NOXO1, NOXA1, NOX1, and NOX4), and release of pro-inflammatory cytokines (IL15, IL7,
5 TNF α , IL6, IL8, and IL11) genes suggesting pro-inflammatory activity of urobilinogen ($p<0.05$).
6 Similar to the previous findings (Flow Cytometry data), in presence of urobilinogen (60uM),
7 prednisolone treatment was not able to significantly reduce the expression of neutrophil
8 activation (NGAL), oxidative stress (NOXO1, NOXA1, and NOX4) and release of pro-
9 inflammatory cytokines (IL7, IL8 and TNF α) again validating the role of urobilinogen in the
10 interference of prednisolone functioning ($p<0.05$, Figure 6B).

11 To further validate the pro-inflammatory nature of urobilinogen, treated PHN
12 (urobilinogen, PMA, LPS) were subjected to proteomics (Figure 6C). Urobilinogen specifically
13 increased the expression of 398 proteins (Figure 6C) associated with inflammation (TNF/NF-kB,
14 TGF β , p38MAPK, ILs, and IFN γ), apoptosis (TRAIL), and other pathways (Figure 6D). Proteins
15 commonly increased by urobilinogen, LPS, and PMA (178+494+341) proteins (Figure 6C) were
16 also linked to pathways TRAIL, TNF, RAC1, p38 MAPK, mTOR, ILs, and others suggesting
17 that urobilinogen shares inflammatory properties similar to LPS and PMA (Supplementary figure
18 14). Urobilinogen specifically did not down-regulate any proteins though proteins downregulated
19 by urobilinogen, LPS, and PMA were linked to transport of fatty acids, organelle biogenesis, and
20 maintenance, metabolism of carbohydrates, extracellular matrix organization, and other
21 pathways (Figure 6D).

22 Next, to validate that urobilinogen modulates prednisolone functioning PHN treated with
23 60uM urobilinogen, PMA, LPS, and PMA/LPS + urobilinogen in combination and then
24 challenged with Prednisolone were subjected to proteomics. Pathway activity (calculated based
25 on the expression of genes belonging to a specific pathway - detailed in supplementary method)
26 of differentially expressed proteins showed a significant increase in IFN-g, IL-5, ERF, TRAIL,
27 VEGF, integrin, and B integrin known inflammatory pathways when treated with
28 urobilinogen/PMA/LPS (Figure 6E). Interestingly, in presence of urobilinogen, prednisolone was
29 not able to significantly reduce the expression of IL-1, P38-MAPK, TGF-B, IL-3, and 5, and
30 GMCSF signalling, p63, C-MYC, biological oxidation, and apoptosis again validating the role of
31 urobilinogen in hindering prednisolone functionality.

1 ***Urobilinogen increases cellular permeability:*** Our results validated that urobilinogen has pro-
2 inflammatory nature and inflammation is more pronounced when urobilinogen is given along
3 with LPS/PMA. Thus, we hypothesized that urobilinogen somehow increased the bioavailability
4 of PMA/LPS. To validate, a permeability assay on PHN was performed (Figure 6F, further
5 detailed in supplementary methods). We observed a significant increase in intracellular staining
6 (MFI) of IFN γ in PHN treated with urobilinogen alone as compared to cytofix/cytoperm-treated
7 PHN suggesting that urobilinogen increased the cellular permeability which resulted in uptake of
8 IFN γ antibody ($p < 0.05$, Figure 6F). This provided the first evidence that urobilinogen not only
9 induces inflammation but also promotes cellular permeability leading to intracellular staining of
10 IFN γ . Taken together, our results provide evidence and validate that urobilinogen is a pro-
11 inflammatory molecule, modulates cell permeability, and also interferes with the functioning of
12 prednisolone.

13 **Urobilinogen modulates glucocorticoid receptor expression and impairs gut integrity:**

14 ***Urobilinogen induces imbalance in GR α / β expression and hampers prednisolone activity:***
15 Glucocorticoids (prednisolone) by binding to GR α receptor are known to trans-activate and
16 trans-repress certain genes to control inflammation. As already known, an increase in GR β
17 expression inhibits the transactivation and trans-repression processes by a dominant negative
18 feedback loop (Figure 7A). Our results showed that inflammation could not be suppressed after
19 prednisolone treatment in PMA/LPS+U stimulated PHN effectively, thus we hypothesized that
20 urobilinogen interferes with glucocorticoid receptor signalling. Therefore, we investigated the
21 expression of two major isoforms of glucocorticoid receptors; GR α and GR β receptors using the
22 DIA-MSMS approach. Analysis revealed that the expression of GR α got reduced and the
23 expression of GR β got enhanced following urobilinogen treatment on neutrophils (Figure 7B).
24 We then further checked the expression status of trans-activated and trans-repressed genes
25 downstream of the glucocorticoid receptor. Targeted proteomics data revealed that the
26 expression of genes known to get repressed such as NF κ B, MAPK-MAP, IRF (Interferon
27 regulatory factor) and CREB post prednisolone administration remained up-stimulated (Figure
28 7C) whereas the expression of trans-active genes such as an inhibitor of NF κ B (I κ B) remained
29 suppressed (Figure 7C). To further validate, we enriched GR-associated genes ($n=1590$) using
30 the Enrichr TRANSFAC library. Of 1590, our proteomic analysis identified 270 proteins.
31 Expression-based pathway activity of these 270 proteins showed that urobilinogen enhanced

1 inflammation (IL6, TNF, TGF β , p38 MAPK, IL1, IFN γ , mTOR), apoptosis (RAC1), and other
2 pathways and the inhibitory capacity of prednisolone for the pathways such as IFN γ , mTOR
3 signalling and cytokine signalling was found to be lower in presence of urobilinogen than that in
4 absence of urobilinogen (as highlighted in the yellow box; expression of IFN γ got significantly
5 reduced when LPS was treated with prednisolone (red to green) but in presence of urobilinogen
6 the expression remained high (red to red-black) respectively) (Figure 7D).

7 ***Urobilinogen modulates junction proteins and contributes to leaky gut:*** Our results showed
8 that urobilinogen modulates cell permeability. Further urobilinogen is produced in the gut by
9 bacterial action on bilirubin. An increase in urobilinogen in the gut could modulate gut integrity.
10 To check, isolated Primary mouse enterocytes (PME) were treated with urobilinogen, LPS
11 (30ng/ml), alcohol (5%), LPS+ 60uM U, and alcohol + 60uM U and subjected to proteomics
12 (Figure 7E). PLS-DA and hierarchical clustering show that the proteomic expression in
13 enterocytes under urobilinogen, LPS+urobilinogen, and alcohol+urobilinogen was similar,
14 whereas, proteomic expression of alcohol and LPS were similar (Figure 7F). Detailed proteomics
15 analysis showed that the majority of proteins associated with tight junction, gap junction,
16 adherent junction, focal adhesion, and cell adhesion were downregulated in comparison to
17 controls ($p < 0.05$, Figure 7G). Expression of proteins associated with the membrane integrity
18 such as gap junction protein 1, occludin, desmoglein, plakoglobin, and desmoplakin got reduced
19 when enterocytes were treated with both alcohol/LPS and urobilinogen suggesting a role of
20 urobilinogen in modulating junction proteins and gut integrity (Figure 7H). Together, these
21 results show the direct role of urobilinogen in modulating glucocorticoid receptor expression,
22 junction proteins, and gut integrity resulting in inflammation inhibition failure and leaky gut
23 respectively in such patients.

24

25

26

1 DISCUSSION

2 In this pilot study, in order to identify the metabolic indicators capable of predicting non-
3 responsiveness (baseline) against corticosteroid therapy in SAH patients, plasma metabolomics
4 using high-resolution mass spectrometry-based (LC-MS) was performed. It is believed that SAH
5 patients at baseline are similar, as also seen in our clinical parameters; but physiologically they
6 appear to be different (WMCNA/heatmap). Therefore, metabolome provides a better insight into
7 responders and non-responders at baseline. Results of our study show that plasma levels of
8 urobilinogen, a major urobilinoid produced in the gut by bacterial action on bilirubin, is capable
9 of segregating NR (independently) and also documented significant association with early
10 mortality in SAH patients. Since urobilinogen is a bacterial metabolized product and was
11 significantly high in circulation, we performed metaproteomics of baseline plasma samples to
12 know bacterial prevalence in NR and found that the Phylum: *Actinobacteria*, *Proteobacteria* and
13 *Firmicutes*, and class *Clostridiales* associated with the metabolism of urobilinogen were high in
14 the circulation as well. Further, investigations suggested that increased plasma levels of
15 urobilinogen not only activated neutrophils and induced the expression of inflammatory genes
16 but also modulated the expression of glucocorticoid receptors thereby contributing to an increase
17 in inflammation leading to a non-responsive phenotype in SAH. We also showed that
18 urobilinogen contributed to an increase in membrane permeability in neutrophils and enterocytes
19 by significantly reducing the expression of junction proteins and contributed to leaky gut
20 phenotype in SAH patients. Thus early identification and clearance of urobilinogen could be one
21 of the therapeutic strategies to prevent corticosteroid NR in SAH patients.

22 A total of 223 patients were enrolled in the study, with 70 patients in the derivative group
23 and 153 in the validation group. At baseline, apart from the increase in bilirubin metabolic
24 product, there was a significant increase in plasma metabolic products of amino acid metabolism,
25 i.e. proteolysis, and fatty acid metabolism, i.e., lipolysis. Both proteolysis and lipolysis are
26 known to be used as fuel by immune cells (11). Our results showed a significant increase in such
27 catabolic processes in the NR at baseline suggesting a relatively more active immune phenotype
28 compared to R. Previous studies have shown the accumulation of cholesterol sulfate (C18043) in
29 the plasma of patients with liver disease. Cholesterol sulfate stabilizes the cell membrane to
30 protect the cell from osmotic lysis (13). A higher accumulation of cholesterol sulfate was seen in
31 the plasma of NR, stipulating more severe cell damage in NR. Further, a higher amount of ATP

1 is produced from the TCA cycle than glucose oxidation (14), and downregulation of the TCA
2 cycle and accumulation of AMP (C00020) (15) in NR reflects an energy-deprived
3 microenvironment. This evidence provides insights into that plasma metabolome can segregate
4 patients who are unlikely to respond to corticosteroid therapy.

5 The effect of prednisolone therapy was evaluated by studying temporal changes in the
6 metabolic profile of R and NR. Our results showed that the prednisolone administration increases
7 the metabolic activity of R throughout the treatment unlike in NR. In R there was an increase in
8 energy metabolism, amino acid synthesis and metabolism, fatty acid metabolism, and vitamin
9 metabolism highlighting functional improvement over time. This was validated using Weighted
10 Metabolite Correlation Network Analysis (WMCNA). The WMCNA in an unsupervised manner,
11 groups the metabolites in the modules sharing similarities in the biological pathways. WMCNA
12 validated inactive metabolic state in NR post corticosteroid treatment. Modular analysis showed
13 that NR has a baseline increase in steroid hormone biosynthesis and vitamin B6 metabolism.
14 Baseline higher level of steroid hormone biosynthesis is one such prominent cause that could
15 lead to feedback inhibition of the corticosteroid given to the patients leading to non-response
16 (16). In addition, pathways such as citrate cycle (TCA cycle), arginine biosynthesis, glutathione
17 metabolism, tyrosine metabolism, glycolysis/gluconeogenesis, and others were stimulated only
18 in R. This observation suggests that corticosteroid exposure specifically induces energy
19 metabolism, arginine metabolism, antioxidant response, and amino acid metabolism in R, which
20 is directly associated with response. WMCNA Modules documented significant correlation with
21 the severity such as baseline NR-specific module 'RED' (increased in NRs) showed direct
22 correlation whereas module 'PINK' (increased in the Rs) showed an inverse correlation with the
23 severity indices (MELD, CTP, DF, and others) respectively. Together the analysis validates the
24 notion that Corticosteroid therapy is effective only in one subset of patients.

25 Based on the AUROC, p-value, FC, and mean decrease in accuracy, a panel of 8
26 metabolites that could segregate NR from R at baseline was identified. On validation in a
27 separate cohort of 156 patients, similarities in the expression pattern of the eight metabolites
28 were observed, thereby validating our results. C05791 (Urobilinogen) augmented the highest
29 AUC of 0.94 and significantly predicted non-response against corticosteroid therapy and
30 mortality with hazard-ratio of 1.5(1.1-1.6). Plasma urobilinogen at 0.07mg/ml cut-off reliably
31 segregated non-survivors (p-value<0.01, log-rank test). In addition, validation by machine

1 learning approach demonstrated the accuracy (98%), sensitivity (99%), and specificity (98.3%)
2 of C05791 (Urobilinogen) as a candidate indicator (non-response and mortality) and Random
3 forest (RF) model as the model of choice for machine learning in SAH patients.

4 As already known that urobilinogen, a bile pigment, is formed by bacterial action on
5 conjugated bilirubin in the intestine (10). Knowing that it is a bacterial product and other
6 bilirubin metabolized products were also high in the plasma of the NR, we looked down into the
7 plasma metaproteomic profile of NR and R. Alpha and beta diversity were significantly high in
8 NR and the level of urobilinogen correlated directly with the bilirubin and urobilinogen
9 converting bacteria *Bacteroides fragilis*, *Clostridium ramosum*, *Clostridium perfringens*, and
10 *Clostridium difficile*.

11 The physiological roles of these urobilinoids are not clear. It has been shown in one study
12 that bilirubin has anti-oxidative activity, reduces adiposity and fatty liver (17). On the contrary, a
13 study on stercobilin suggested that it not only has pro-inflammatory activity but also alters lipid
14 metabolism in obesity/ diabetes mellitus (18) (10). Our study demonstrated that urobilinogen not
15 only induces inflammation in the neutrophils but also alters the expression of glucocorticoid-
16 alpha receptor diverging response for steroids toward non-response.

17 Prednisolone is known to reduce inflammation but when neutrophils were tweaked with
18 PMA/LPS, urobilinogen, and prednisolone, prednisolone couldn't effectively reduce the
19 inflammation. This gave the clue that urobilinogen must be interfering with glucocorticoid
20 signaling. To further introspect, we checked the expression of GR α and GR β in neutrophils
21 treated with urobilinogen. When compared to control, expression of GR α (essential for
22 prednisolone response) got reduced post urobilinogen stimulation whereas the expression of GR β
23 (associated with dominant feedback inhibition of GR α response (19) got enhanced post-treatment
24 with urobilinogen. This suggests that high and persistent levels of urobilinogen in the plasma of
25 SAH patients may drive them to have severe inflammation and develop resistance to
26 corticosteroid therapy.

27 Our data also showed that when neutrophils were treated in combination with both
28 PMA/LPS and urobilinogen, inflammation increased to several folds. This suggested that maybe
29 urobilinogen increases the bioavailability of inflammatory molecules and increases
30 inflammation. Results of this study clearly demonstrated that urobilinogen modulates cellular

1 permeability thereby inducing the labelling of the intracellular cytokine IFN γ . These results
2 provide the first evidence that overexposure to urobilinogen at a higher concentration is capable
3 of modulating cellular permeability.

4 Since urobilinogen is produced in large amounts in the gut (10), intestinal cells are
5 persistently exposed to a higher concentration of urobilinogen. This then may affect the
6 membrane stability and contributes to leaky gut in such patients. Urobilinogen exposure at a
7 higher concentration on the primary mice enterocytes showed a significant decrease in the tight
8 junction, gap junction, adherent junction, focal adhesion, and cell adhesion proteins ($p < 0.05$)
9 specifically the expression of proteins associated with the membrane integrity such as gap
10 junction protein 1, occludin, desmoglein, plakoglobin, and desmoplakin got reduced on treatment
11 with urobilinogen in combination with alcohol/LPS suggesting a role of urobilinogen in the
12 modulation of junction proteins and gut integrity.

13 In conclusion, in non-responders, a change in microbiome diversity; particularly an
14 increase of bilirubin metabolizing microbiome (*Clostridiales*), converts the bilirubin to
15 urobilinogen, in the gut. Increased gut urobilinogen levels, start a vicious cycle of dysbiosis by
16 acting on the intestinal cells (enterocytes); impacting their cell membrane integrity by
17 dysregulating tight junction, gap junction, adherent junction, focal adhesion, and cell adhesion
18 proteins and promoting leaky gut. Increased dysbiosis (bilirubin metabolizing bacteria)
19 contributes to the increase in circulatory urobilinogen level (increased bilirubin metabolism)
20 which induces immune flare by activating neutrophils. Circulating urobilinogen also
21 dysregulates the glucocorticoid receptors (increases GR β and decreases GR α) thereby
22 contributing to non-response against corticosteroid therapy in patients with SAH (Figure 8).

23 This study has the limitation of being monocentric. Future multicentre studies should be
24 performed with metabolomics and meta-proteomics in large series of patients with SAH.

25 To conclude, baseline plasma metabolome and meta-proteome discriminate corticosteroid
26 NRs from Rs. Further, bacterial-derived urobilinogen induces inflammation, modulates intestinal
27 permeability, and predicts outcomes in Severe Alcoholic Hepatitis.

28

29

1 **References:**

- 2 1. Osna NA, Donohue TM, Jr., Kharbanda KK. Alcoholic Liver Disease: Pathogenesis and Current
3 Management. *Alcohol Res* 2017;38:147-161.
- 4 2. Mitchell MC, Friedman LS, McClain CJ. Medical Management of Severe Alcoholic Hepatitis:
5 Expert Review from the Clinical Practice Updates Committee of the AGA Institute. *Clin Gastroenterol*
6 *Hepatol* 2017;15:5-12.
- 7 3. Kadian M, Kakkar R, Dhar M, Kaushik RM. Model for end-stage liver disease score versus
8 Maddrey discriminant function score in assessing short-term outcome in alcoholic hepatitis. *J*
9 *Gastroenterol Hepatol* 2014;29:581-588.
- 10 4. Aithal GP, Guha N, Fallowfield J, Castera L, Jackson AP. Biomarkers in liver disease: emerging
11 methods and potential applications. *Int J Hepatol* 2012;2012:437508.
- 12 5. Saberi B, Dadabhai AS, Jang YY, Gurakar A, Mezey E. Current Management of Alcoholic Hepatitis
13 and Future Therapies. *J Clin Transl Hepatol* 2016;4:113-122.
- 14 6. Shasthry SM, Sarin SK. New treatment options for alcoholic hepatitis. *World J Gastroenterol*
15 2016;22:3892-3906.
- 16 7. Sarin SK, Sharma S. Predictors of steroid non-response and new approaches in severe alcoholic
17 hepatitis. *Clin Mol Hepatol* 2020;26:639-651.
- 18 8. Dao A, Rangnekar AS. Steroids for Severe Alcoholic Hepatitis: More Risk Than Reward? *Clinical*
19 *Liver Disease* 2018;12:151-153.
- 20 9. Maras JS, Das S, Sharma S, Shasthry SM, Colsch B, Junot C, Moreau R, et al. Baseline urine
21 metabolic phenotype in patients with severe alcoholic hepatitis and its association with outcome.
22 *Hepatol Commun* 2018;2:628-643.
- 23 10. Zhang A, Sun H, Yan G, Wang P, Wang X. Metabolomics for Biomarker Discovery: Moving to the
24 Clinic. *Biomed Res Int* 2015;2015:354671.
- 25 11. Zhang A, Sun H, Yan G, Wang P, Wang X. Metabolomics for Biomarker Discovery: Moving to the
26 Clinic. *BioMed Research International* 2015;2015:1-6.
- 27 12. Moreau R, Claria J, Aguilar F, Fenaille F, Lozano JJ, Junot C, Colsch B, et al. Blood metabolomics
28 uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF.
29 *J Hepatol* 2020;72:688-701.
- 30 13. Michelena J, Alonso C, Martinez-Arranz I, Altamirano J, Mayo R, Sancho-Bru P, Bataller R, et al.
31 Metabolomics Discloses a New Non-invasive Method for the Diagnosis and Prognosis of Patients with
32 Alcoholic Hepatitis. *Ann Hepatol* 2019;18:144-154.
- 33 14. Mendez-Sanchez N, Valencia-Rodriguez A, Vera-Barajas A, Abenavoli L, Scarpellini E, Ponciano-
34 Rodriguez G, Wang DQ. The mechanism of dysbiosis in alcoholic liver disease leading to liver cancer.
35 *Hepatoma Res* 2020;6.
- 36 15. Hartmann P, Seebauer CT, Schnabl B. Alcoholic liver disease: the gut microbiome and liver cross
37 talk. *Alcohol Clin Exp Res* 2015;39:763-775.
- 38 16. Karakike E, Moreno C, Gustot T. Infections in severe alcoholic hepatitis. *Ann Gastroenterol*
39 2017;30:152-160.
- 40 17. Puri P, Liangpunsakul S, Christensen JE, Shah VH, Kamath PS, Gores GJ, Walker S, et al. The
41 circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis.
42 *Hepatology* 2018;67:1284-1302.
- 43 18. Wang R, He M, Xu J. Serum bilirubin level correlates with mortality in patients with traumatic
44 brain injury. *Medicine (Baltimore)* 2020;99:e21020.
- 45 19. Hamoud AR, Weaver L, Stec DE, Hinds TD, Jr. Bilirubin in the Liver-Gut Signaling Axis. *Trends*
46 *Endocrinol Metab* 2018;29:140-150.
- 47 20. Sanada S, Suzuki T, Nagata A, Hashidume T, Yoshikawa Y, Miyoshi N. Intestinal microbial
48 metabolite stercobilin involvement in the chronic inflammation of ob/ob mice. *Sci Rep* 2020;10:6479.
- 49 21. Das S, Maras JS, Hussain MS, Sharma S, David P, Sukriti S, Shasthry SM, et al. Hydroxylated
50 albumin modulates neutrophils to induce oxidative stress and inflammation in severe alcoholic hepatitis.
51 *Hepatology* 2017;65:631-646.
- 52 22. Ganeshan K, Nikkanen J, Man K, Leong YA, Sogawa Y, Maschek JA, Van Ry T, et al. Energetic
53 Trade-Offs and Hypometabolic States Promote Disease Tolerance. *Cell* 2019;177:399-413 e312.
- 54 23. Tamasawa N, Tamasawa A, Takebe K. Higher levels of plasma cholesterol sulfate in patients with
55 liver cirrhosis and hypercholesterolemia. *Lipids* 1993;28:833-836.
- 56 24. Rui L. Energy metabolism in the liver. *Compr Physiol* 2014;4:177-197.
- 57 25. Huang Y, Niu M, Jing J, Zhang ZT, Zhao X, Chen SS, Li SS, et al. Metabolomic Analysis Uncovers
58 Energy Supply Disturbance as an Underlying Mechanism of the Development of Alcohol-Associated Liver
59 Cirrhosis. *Hepatology Communications* 2021;5:961-975.
- 60 26. Schiffer L, Barnard L, Baranowski ES, Gilligan LC, Taylor AE, Arlt W, Shackleton CHL, et al. Human
61 steroid biosynthesis, metabolism and excretion are differentially reflected by serum and urine steroid
62 metabolomes: A comprehensive review. *J Steroid Biochem Mol Biol* 2019;194:105439.
- 63 27. Hinds TD, Jr., Adeosun SO, Alamodi AA, Stec DE. Does bilirubin prevent hepatic steatosis through
64 activation of the PPARalpha nuclear receptor? *Med Hypotheses* 2016;95:54-57.

- 1 28. Stec DE, John K, Trabbic CJ, Luniwal A, Hankins MW, Baum J, Hinds TD, Jr. Bilirubin Binding to
- 2 PPARalpha Inhibits Lipid Accumulation. PLoS One 2016;11:e0153427.
- 3 29. Ramamoorthy S, Cidlowski JA. Corticosteroids: Mechanisms of Action in Health and Disease.
- 4 Rheum Dis Clin North Am 2016;42:15-31, vii.

5

6

1 **Figure 1: Baseline Plasma Metabolome Robustly Distinguishes Non Responders (NR):**

2 **1A.** Flow chart explains the blueprint of this study. 223 patients were enrolled and their
3 metabolic profile was studied at baseline, day3 and day7. Baseline metabolomic and meta-
4 proteomic profile were integrated to identify the host-microbiome interactions. Metabolomics
5 was used to identify the baseline indicator capable of segregating NR and R at baseline.
6 Functional properties of identified indicator of non-response as indicated were also investigated.

7 **1B.** Volcano plot shows differentially expressed metabolites between NR and R at baseline. Y-
8 axis corresponds to $-\log_{10}$ p-value, and x-axis corresponds to \log_2 fold change. The green
9 colour in background indicates the differentially downregulated metabolites whereas red colour
10 in background highlights the differentially upregulated metabolites at baseline. Encircled
11 metabolites highlights the panel of metabolites which were selected to segregate responders and
12 non-responders.

13 **1C.** Partial least squares discriminant analysis (PLS-DA) score plot shows distinct metabotype of
14 NR (red dot) and R (green dot) at baseline.

15 **1D.** Dot plot shows KEGG pathway enrichment analysis of metabolites with significantly higher
16 expression at baseline in NR compared to R ($FC \pm 1.5$, $p\text{-value} < 0.05$).

17 **1E.** Dot plot shows KEGG pathway enrichment analysis of metabolites with lower expression at
18 baseline in NR compared to R ($FC \pm 1.5$, $p\text{-value} < 0.05$).

19 **Figure2. Corticosteroid mediated changes in the metabolic profile:**

20 **2A.** Volcano plot displaying temporal changes in expression of metabolites in NR vs. R at
21 baseline and post-initiation of corticosteroid therapy at day 3, and day 7. Red dots correspond to
22 higher expression ($FC > 1.5$, $p\text{-value} < 0.05$) of metabolites in plasma, whereas green corresponds
23 to lower expression ($FC < 1.5$, $p\text{-value} < 0.05$) in NR respectively.

24 **2B.** Partial least squares – discriminant analysis score plot showing increased bifurcation in the
25 metabolic profile of NR and R post initiation of corticosteroid therapy at day 3 and day 7.
26 Multivariate heatmap showing the expression of metabolites at different days i.e. at baseline, day
27 3 and day 7 in NR and R. The R is represented by orange, and the NR is represented by
28 turquoise, respectively.

1 **2C.** Weighted Metabolite Co-expressed Network Analysis (WMCNA) followed by Hierarchical
2 clustering showing 9 modules of co-expressed metabolites in NR and R highlighted by different
3 colour bars. The heatmap shows the expression of modules (cluster of metabolites) in NR and R
4 at baseline, Day 3 and Day 7.

5 **2D.** Heatmap showing module trait (R, NR at baseline, Day 3 and Day 7) relationship identified
6 by WMCNA. Each module is represented by the colour name. Expression of the module ranges
7 from red (upregulated) to green (downregulated). Module red is NR specific (upregulated in NR
8 at baseline) whereas pink module is R specific.

9 **2E.** Pathway enrichment analysis. Each coloured-panel in the figure corresponds to pathways
10 significantly associated with module of respective colour (p-value <0.05).

11 **2F.** Correlation plot indicating the correlation of 9 identified modules with clinical parameters at
12 baseline, day 3, and day 7 respectively.

13 **Figure 3. Baseline Plasma Level of Urobilinogen segregates R and NR:**

14 **3A.** Flow chart representing approach used to identify metabolic indicators of non-response at
15 baseline and mortality prediction.

16 **3B.** Whisker plot showing expression of top potential metabolites (p-value<0.05, FC±1.5) to
17 predict non-response in derivative cohort and validation cohort at baseline. Metabolites C00020,
18 C05791, C00078, C00439, and C18043 were upregulated and exhibited similar expression in
19 derivative and validation cohorts, whereas C01835, C00785, and C00178 were downregulated in
20 NRs. Red colour depicts NRs, and green colour depicts R.

21 **3C.** Tables showing AUROC and univariate Cox regression analysis of the most significant
22 metabolites capable of predicting non-response against corticosteroids based on their baseline
23 levels respectively. AUC of C05791 (Urobilinogen) was found to be the highest and most
24 significant for the determination of non-response in SAH patients

25 **3D.** Kaplan Meier curve plotted for one-month mortality based on the cut of the level of
26 Urobilinogen. Our results highlight that SAH patients with a plasma level of C05791 more than
27 0.07mg/ml were highly predisposed to non-response against corticosteroid treatment. Log-rank
28 was found to be significant (p<0.05).

1 **3E.** Comparison of AUROC of Urobilinogen with the severity scores for the prediction of
2 mortality in SAH patients. The AUROC of Urobilinogen was better than CTP, MELD, and DF
3 Score in SAH patients.

4 **3F.** Machine learning-based method establishes that the accuracy, sensitivity, specificity, and p-
5 value of urobilinogen as compared to CTP, DF, and MELD score. The confusion matrix of the
6 random forest was the most appropriate model for segregating responders from non-responders.

7 **Figure 4: Baseline plasma meta-proteomics (microbiome) reflects high prevalence of**
8 **bacteria in Non-Responders:**

9 **4A.** Bar plot showing significant increase in metabolites (p-value<0.05, FC±1.5) associated with
10 bilirubin metabolism. Another panel depicts bilirubin and urobilinogen metabolism in the body.

11 **4B.** Shannon and Simpson index showing an increase in alpha diversity in plasma of NR.

12 **4C.** Beta diversity plot showing distinct metaproteome composition of NR and R.

13 **4D.** Bar plot showing an increase in prevalence of metaproteome particularly, *Actinobacteria*,
14 *Firmicutes* and *Proteobacteria* in the plasma of NR.

15 **4E.** LDA (Least discriminant analysis) plot showing bacteria uniquely present in plasma of NR
16 and R.

17 **4F.** Bar plot showing functional assessment of identified metaproteome in R and NR. A
18 significant increase in biosynthesis of secondary metabolites was found in NR (p-value<0.05,
19 FC±1.5).

20 **Figure 5 Integration of plasma metabolome and meta-proteome**

21 **5A.** Flow diagram of method adopted to correlate metaproteome and metabolome.

22 **5B.** Correlation clustering of baseline differentially expressed metabolites and metaproteins.
23 Cluster 2 is urobilinogen specific cluster.

24 **5C.** Correlation Network map displaying bacteria correlating with urobilinogen ($R^1 > 0.7$).
25 Bacteria belonging to *Firmicutes* and *Proteobacteria* correlated directly with urobilinogen.

26 **5D.** Heatmap showing expression of urobilinogen and bacteria correlated with urobilinogen in
27 NR and R at baseline.

1 **Figure 6: Urobilinogen activates neutrophils, induces respiratory burst and increases**
2 **cellular permeability:**

3 **6A. Panel A)** Representative images of flow cytometry dot plots showing the neutrophil
4 CD11b+ and CD66+ population. **Panel B, C, D)** Graphs representing increase in MFI expression
5 of H2DCFDA (ROS generation), CXCR1+, and TNFa+ in a dose dependent treatment of
6 urobilinogen on neutrophil. Highest MFI for ROS, neutrophil activation and inflammation was
7 observed at 60uM urobilinogen treatment respectively. **Panel E,F)** Graphs representing increase
8 in MFI post PMA/LPS/ Urobilinogen treatment on neutrophils and inefficiency of prednisolone
9 to reduce inflammation (TNFa+ population) and ROS generation (H2DCFDA population)
10 effectively in neutrophils treated with PMA/LPS and urobilinogen.

11 **6B.** Panel showing expression of genes associated with activation of neutrophils, oxidative
12 stress, antioxidants and inflammatory cytokines. Orange colour bar plots show expression of
13 genes in PMA/Urobilinogen/Prednisolone treated PHN whereas blue bar plots shows expression
14 of genes in LPS/Urobilinogen/Prednisolone treated PHN. Star mark highlights significant change
15 in expression.

16 **6C.** Heatmap shows expression of total enriched proteins in PMA, LPS and urobilinogen treated
17 PHN. Red colour venn diagram represents the proteins which got upregulated post
18 urobilinogen/PMA or LPS treatment respectively (p-value<0.05, FC±1.5). Green colour venn
19 diagram represents the proteins which got upregulated post urobilinogen/PMA or LPS treatment
20 respectively (p-value<0.05, FC±1.5).

21 **6D.** Dot plot represents the pathways got significantly (p-value<0.05, FC>1.5) upregulated in
22 PHN upon urobilinogen treatment alone and got downregulated (p-value<0.05, FC<-1.5) in PHN
23 upon PMA/LPS/urobilinogen treatment.

24 **6E.** Heatmap represents expression of proteins enriched globally in PHN treated under different
25 conditions highlighted in the figure. Panel 1 shows the pathway activity of different pathways in
26 different groups as mentioned in the figure. Numerical values in the bracket highlights the
27 number of proteins enriched in each pathways.

28 **6F.** Representative histogram and bar plot of IFNg-MFI measured post urobilinogen treatment
29 on neutrophils to assess the permeability capacity of urobilinogen. Bar plot shows high MFI in
30 urobilinogen treated samples compared to positive controls treated with cytofix and cytoperm.

1 **Figure 7: Urobilinogen modulates glucocorticoid receptor expression and impairs gut**
2 **integrity**

3 **7A.** Figure representing the functional role of GR α and GR β receptor and its mechanism of
4 regulation. Increase in GR β expression dominantly repress the GR α .

5 **7B.** Bar plot showing expression of GR α and GR β in PHN treated with 60uM urobilinogen (p-
6 value<0.05, FC>1.5).

7 **7C.** Bar plot showing expression of molecules present in GR α downstream signalling. Y axis
8 represents the fold change.

9 **7D.** Pie chart here represents 270 genes enriched in our data out of 1590 NR3C1 associated
10 reported genes. Heatmap represents the pathway activity of pathways associated with the
11 enriched genes. Numerical values in the bracket represents number of genes enriched in the
12 respective pathway. Pink and yellow box highlights the increase in inflammatory pathways upon
13 PMA/LPS and urobilinogen administration and inefficiency of prednisolone to effectively
14 downregulate inflammatory pathways.

15 **7E.** Pictorial representation of permeability assay performed on enterocytes to assess the effect
16 of urobilinogen on membrane integrity.

17 **7F.** PLS-DA plot showing variability in the enterocytes treated with Urobilinogen, LPS, and
18 alcohol. Heatmap represents the expression of proteins under different treatment conditions and
19 highlights that urobilinogen has almost similar effects as LPS has on enterocytes.








20 **7G.** Bar plot showing change in expression (p-value<0.05, FC>1.5) of proteins associated with
21 Tight junction, gap junction, focal adhesion, cell adhesion, and adherent junction. Red colour
22 represents the percent of proteins significantly upregulated post 60uM urobilinogen treatment
23 and green colour represents the percent of proteins significantly downregulated post 60uM
24 urobilinogen treatment.



25 **7H.** Bar plot shows the expression of desmoplakin, gap junction protein 1, occludin, desmoglein,
26 and plakoglobin post treatment with urobilinogen, LPS and alcohol. Green bar represents
27 downregulation and red represents upregulation.

28

1 **Figure 8: Graphical Abstract**

2 Our study highlights that severe alcoholic hepatitis particularly among Non-responders has a
3 high circulating bilirubin and its metabolic product urobilinogen. We also found an increase in
4 bacteria specifically bacteria metabolizing bilirubin to urobilinogen in plasma of SAH-NR. This
5 study highlights an increase in circulating urobilinogen in NR modulates: 1) gut integrity by
6 downregulating junction proteins in the enterocytes. 2) Activates circulating neutrophils and
7 induces flare of inflammation 3) Increases the expression of GR β which further inhibits GR α
8 expression and dependent response. Urobilinogen inhibited trans-repression (inflammatory
9 genes) and transactivation (anti-inflammatory genes) of genes under GR α thereby generating
10 resistance against corticosteroid therapy seen in SAH patients. Finally, our results proposed a
11 vicious cycle of urobilinogen: Urobilinogen \rightarrow alters gut integrity \rightarrow increase in bacterial
12 translocation \rightarrow metabolism of bilirubin to urobilinogen $\rightarrow\rightarrow$ alteration of gut integrity,
13 activation of neutrophil, modulation of GR response.






C

Area Under the Curve


Test Result Variable(s)	Area	Std. Error ^a	Asymptotic Sig. ^b	Asymptotic 95% Confidence Interval	
				Lower Bound	Upper Bound
				C00020	0.711
C00178	0.325	0.053	0.001	0.221	0.428
C00785	0.632	0.039	0.011	0.554	0.709
C18043	0.756	0.059	0.001	0.641	0.871
C00439	0.701	0.061	0.001	0.581	0.821
C02835	0.356	0.043	0.006	0.271	0.442
C05791	0.947	0.014	0.001	0.919	0.975
C00078	0.688	0.033	0.001	0.623	0.753

Test Result Variable(s)	Univariate Analysis					Multivariate Analysis					
	Wald	Sig.	HR	95.0% CI for Exp(B)		Test Result Variable(s)	Wald	Sig.	HR	95.0% CI for Exp(B)	
				Lower	Upper					Lower	Upper
C00020	6.025	0.014	1.133	1.026	1.252	C00020	0.003	0.958	0.998	0.915	1.088
C05791	37.422	0.000	1.384	1.247	1.535	C05791	31.52	0.000	1.469	1.284	1.679
C18043	3.975	0.046	1.071	1.001	1.145	C18043	0.894	0.344	0.972	0.916	1.031
C00178	8.115	0.004	0.879	0.805	0.961	-	-	-	-	-	-
C00785	2.959	0.085	1.112	0.985	1.256	-	-	-	-	-	-
C00439	2.348	0.125	1.084	0.978	1.201	-	-	-	-	-	-
C02835	2.96	0.085	0.857	0.718	1.022	-	-	-	-	-	-
C00078	0.006	0.94	1.007	0.837	1.211	-	-	-	-	-	-
CTP_D0	33.553	0.000	26.389	8.719	79.869	CTP_D0	0.721	0.396	1.489	0.594	3.731
DF_D0	39.926	0.000	1.148	1.1	1.199	DF_D0	7.52	0.006	1.053	1.015	1.093
MELD_D0	58.997	0.000	1.884	1.603	2.215	MELD_D0	0.986	0.321	0.914	0.766	1.091



F




	-log10 p-value	Specificity	Sensitivity	Accuracy	
C05791	3.1218	0.962	0.649	0.91	lda svm rf knn cart
CTP	0.326	0.96	0.027	0.839	
MELD	1.967	0.919	0.811	0.883	
DF	3.6983	0.984	0	0.843	
C05791	7.637	0.979	0.838	0.985	
CTP	8.4878	0.986	0.027	0.834	
MELD	6.265	0.969	0.865	0.901	
DF	8.4878	0.919	0.405	0.834	
C05791	15.658	0.983	0.99	0.98	
CTP	7.265	0.969	0	0.989	
MELD	2.534	0.919	0.811	0.901	
DF	1.2274	0.909	0.162	0.825	
C05791	3.1218	0.962	0.649	0.91	
CTP	7.4878	0.983	0	0.834	
MELD	2.534	0.919	0.811	0.901	
DF	4.4378	0.984	0.162	0.848	













Confusion Matrix


Reference

Prediction	C05791		CTP		MELD		DF	
	NR	R	NR	R	NR	R	NR	R
lda	24	7	1	0	17	6	8	6
svm	31	4	0	0	30	15	0	0
rf	37	0	1	0	32	15	24	15
knn	31	4	1	0	30	15	15	17
cart	24	7	0	0	30	15	6	3
	13	179	36	186	20	180	29	180
	6	182	37	186	7	171	37	186
	0	186	36	186	5	171	13	171
	6	182	36	186	7	171	22	169
	13	179	37	186	7	171	31	183









Our results proposed a vicious cycle of urobilinogen: Urobilinogen → alters gut integrity → increase in bacterial translocation → metabolism of bilirubin to urobilinogen → alteration of gut integrity, activation of neutrophil, modulation of GR response.